{"created":"2015-05-14T19:56:44+00:00","modified":"2015-05-14T19:56:44+00:00","valid":{"from":"2014-04-22T10:02:38+00:00","to":"3014-04-22T10:02:38+00:00"},"hreflang":"en","guid":"56a7b7c4-97a1-4ce7-81b3-4811705051e4","published":"2014-04-22T10:02:38+00:00","contenttemplated":"[{\"content\":\"<p>Activist investor William Ackman has set his eyes on a new target: Allergan.</p>\",\"type\":\"text/html\"},{\"type\":\"text/html\",\"content\":\"<p>Ackman has joined forces with Valeant Pharmaceuticals to purchase the Botox-maker for an undisclosed amount -- <a href=\\\"http://dealbook.nytimes.com/2014/04/21/william-ackman-and-drug-maker-prepare-bid-for-botox-maker/?_php=true&amp;_type=blogs&amp;hpw&amp;rref=business&amp;_r=0\\\" target=\\\"_self\\\">$50 billion</a> is one educated guess. <span>Ackman along with other so-called corporate raiders Carl Icahn and Nelson Peltz, have become famous, and sometimes infamous, for shaking up the companies they invest in.</span></p>\"},{\"type\":\"text/html\",\"content\":\"<p><span>Do they do more harm than good?</span></p>\"},{\"content\":\"<p><span>Bloomberg News reporter Tara Lachapelle joins Marketplace Morning Report host David Brancaccio to discuss the track record of activist investors, noting that </span><a href=\\\"http://www.bloomberg.com/news/2014-03-31/raiders-turned-activists-prove-boon-for-stocks-beating-s-p-500.html\\\" target=\\\"_blank\\\">more often than not</a><span>, these in-it-to-win-it investors are actually a shareholder&apos;s friend.</span></p>\",\"type\":\"text/html\"},{\"content\":\"<p><em>Click on the audio player above to hear more. </em></p>\",\"type\":\"text/html\"}]","byline":"David Brancaccio","teaser":"A new study says activist investors generated 48 percent average gain for companies they targeted.","itags":["Marketplace Morning Report","56a7b7c497a1ce7a1b3c4811705051e4","Marketplace Morning Report for Tuesday April 22, 2014","Marketplace","PMP:Marketplace_PMP"],"tags":["activist investing","Bill Ackman","Allergan","APM","Business"],"description":"A new study says activist investors generated 48 percent average gain for companies they targeted.","title":"Activist investors help shareholders, right?","contentencoded":"<div class=\"barn-cleaned\"><p>Activist investor William Ackman has set his eyes on a new target: Allergan.</p>\n<p>Ackman has joined forces with Valeant Pharmaceuticals to purchase the Botox-maker for an undisclosed amount -- <a href=\"http://dealbook.nytimes.com/2014/04/21/william-ackman-and-drug-maker-prepare-bid-for-botox-maker/?_php=true&amp;_type=blogs&amp;hpw&amp;rref=business&amp;_r=0\" target=\"_self\">$50 billion</a> is one educated guess.&nbsp;<span>Ackman along with other so-called corporate raiders Carl Icahn and Nelson Peltz, have become famous, and sometimes infamous, for shaking up the companies they invest in.</span></p>\n<p><span>Do they do more harm than good?</span></p>\n<p><span>Bloomberg News reporter Tara Lachapelle joins Marketplace Morning Report host David Brancaccio to discuss the track record of activist investors, noting that&nbsp;</span><a href=\"http://www.bloomberg.com/news/2014-03-31/raiders-turned-activists-prove-boon-for-stocks-beating-s-p-500.html\" target=\"_blank\">more often than not</a><span>, these in-it-to-win-it investors are actually a shareholder's friend.</span></p>\n<p><em>Click on the audio player above to hear more.&nbsp;</em></p></div>","audio":[{"type":"image/jpeg","href":"http://www.marketplace.org/sites/default/files/styles/primary-image-610x340/public/760977.jpg?itok=F45njwS6","meta":{"height":"340","crop":"primary","width":"610"}},{"type":"audio/mpeg","href":"http://play.publicradio.org/pmp/d/podcast/marketplace/segments/2014/04/22/marketplace_segment05_20140422_64.mp3","meta":{"duration_hms":"00:02:39","api":{"type":"application/json","href":"http://api.publicradio.org/audio/v2?ref=pmp&id=apm-audio:/marketplace/segments/2014/04/22/marketplace_segment05_20140422"},"duration":159},"format":"MP3"}]}